Ablation Not Linked to Longer Survival in Oligometastatic Breast Cancer
A trial found that ablation did not improve survival in patients with oligometastatic breast cancer compared to systemic therapy alone. The results challenge routine use of ablation outside of symptom control.
Patients with oligometastatic breast cancer and clinicians managing such cases may need to reconsider ablation's role. Evidence comes from a trial, though its size and design are not detailed.
- population
- patients with oligometastatic breast cancer
Taken from the source as published — check the details before acting on them.
Clinical implications
The findings suggest ablation may not be effective for extending survival in this patient group.
Common questions
What was the main finding of the trial?
The trial found that ablation did not improve survival in patients with oligometastatic breast cancer compared to systemic therapy alone.
Does this mean ablation has no role in treating this condition?
The study suggests ablation may not extend survival, but it may still be used for symptom control.
Sources
- Ablation Falls Short in Oligometastatic Breast Cancer Trial Medscape · medscape.com
Headlines and links belong to the publishers listed above. The summary above is written by The Health Brief; see how this works.
